The technical approach behind these numbers is worth noting. Rather than relying on a single broad screening assay, the team used polymerase chain reaction amplification combined with flow-through hybridization, a method that allows simultaneous detection and identification of 21 distinct HPV genotypes. This matters because HPV is not one pathogen but a family of more than 200 related viruses, only some of which are classified as high-risk for cancer. Distinguishing which genotypes circulate in a given population is essential for predicting how well existing vaccines will perform and for designing regional screening programs that target the types actually present.

The five most frequently detected genotypes among the men were HPV6, HPV52, HPV16, HPV51, and HPV42. This list mixes low-risk and high-risk types: HPV6 and HPV42 are classified as low-risk, typically associated with genital warts rather than malignancy, while HPV52, HPV16, and HPV51 belong to the high-risk category linked to anogenital and oropharyngeal cancers. HPV16 is the single most carcinogenic genotype worldwide and a dominant driver of HPV-positive cancers in both sexes. The fact that it ranks among the top types in these male outpatients reinforces why vaccination and, eventually, male screening remain central to cancer prevention efforts.

One of the study’s most striking findings is the overlap between the genotypes circulating in men and those previously reported in local women in the Putian region. The predominant types in the male cohort, including low-risk HPV6 and HPV42 and high-risk HPV52, HPV51, and HPV16, substantially mirror the genotype distribution described for females in the same area. Such concordance is consistent with sexual transmission within partner networks and suggests that vaccinating or screening only one sex leaves a persistent viral reservoir in the other. The authors argue that this overlap supports including men in HPV prevention strategies and may inform future evaluation of partner-oriented prevention approaches, in which couples are considered jointly rather than in isolation.

Age emerged as a significant axis of variation. Prevalence was highest among patients older than 60 years, a pattern that contrasts with the classic bimodal age distribution often described in women, where infection peaks in young adulthood and again around midlife. In men, clearance of infection can be less efficient with age, and cumulative exposure over a lifetime may raise the probability of detectable infection in older age groups. The researchers also conducted sensitivity analyses using broader age categories, combining the 51-to-60 and over-60 groups, to confirm the robustness of the association between older age and high-risk HPV infection, indicating that the age signal was not an artifact of how the categories were drawn.

Clinical diagnosis also shaped the picture. HPV prevalence varied significantly across the six diagnostic subgroups into which patients were stratified: warts, urinary tract infections, dermatitis, genital diseases, health check-ups, and others. The warts group showed the highest infection rate at 48.7 percent, dominated by HPV6 and HPV11, the two low-risk genotypes most classically responsible for condyloma acuminatum, or genital warts. That result is biologically coherent, since patients presenting with visible warts are, by definition, already expressing an HPV-driven lesion. More unexpected was the dermatitis group, which came in a close second at 46.5 percent and displayed remarkable genotype diversity, with HPV52, HPV16, HPV42, HPV51, and HPV59 all appearing among the detected types.

The dermatitis finding carried enough statistical weight to survive multivariable regression analysis. After adjusting for other variables, dermatitis was identified as an independent risk factor for high-risk HPV infection, with the authors reporting an adjusted odds ratio and controlling for confounding using generalized variance inflation factors to check for collinearity among predictors. The biological interpretation is not settled from these data alone, but plausible mechanisms include disruption of the skin barrier providing an easier entry point for virions, local immune dysregulation reducing viral clearance, or inflammatory conditions serving as a marker for behaviors or exposures that also raise HPV risk. Whatever the direction of causality, the association suggests that dermatology clinics could represent an underused point of contact for HPV testing in men.

The vaccine analysis is where the study’s public health implications become most concrete. China’s regional vaccination programs have historically focused on girls and women, and the 9-valent HPV vaccine, which protects against genotypes 6, 11, 16, 18, 31, 33, 45, 52, and 58, is the broadest formulation in widespread use. Yet even against this nine-type panel, the researchers calculated that 33.5 percent of HPV-positive men in the cohort carried at least one genotype not covered by the vaccine, and the coverage gap was nearly identical, at 33.9 percent, among men carrying high-risk types. In other words, roughly one third of infections, including those with cancer-associated potential, would not be prevented by the current nonavalent vaccine, a gap driven by types such as HPV51 and HPV59 that fall outside the formulation.

These coverage gaps do not diminish the case for vaccination, but they do complicate it. On one hand, the predominance of HPV6, HPV16, and HPV52 in the male cohort means the 9-valent vaccine would still address a majority of circulating infections, and HPV16 in particular is responsible for a disproportionate share of HPV-related cancers. On the other hand, the persistence of a substantial non-vaccine reservoir means that vaccination alone cannot eliminate transmission in this population, and the finding strengthens arguments for extending vaccination to boys and men, both to protect them directly against cancers and warts and to build herd protection that benefits unvaccinated partners.

The study has limitations inherent to its design. It was retrospective and drew exclusively on male outpatients at a single hospital in Putian, a prefecture-level city in Fujian Province, so the 35.2 percent prevalence cannot be generalized to the general male population, which typically shows lower rates than clinic-based cohorts. Patients visiting dermatology or urology clinics are more likely to have conditions related to or coinciding with HPV infection than men sampled at random. The ethics committee of the First Hospital of Putian City approved the study and granted an exemption from individual informed consent, and the authors declare no competing interests. Even with those caveats, the work fills a genuine gap: no previous research on male HPV prevalence in Putian had been reported, and region-specific genotype data of this kind are scarce across much of China.

The broader takeaway is that HPV epidemiology in men deserves the same granular, genotype-level attention that has long been applied to women. As vaccination programs expand and as oropharyngeal and anal cancers linked to HPV rise in many countries, understanding which types circulate in male populations, at which ages, and in association with which clinical conditions becomes essential for modeling transmission, forecasting vaccine impact, and deciding whether and when to introduce routine male screening. The Putian data, with their high prevalence, distinctive age gradient, dermatitis signal, and measurable vaccine gap, offer a template for the kind of local surveillance that global HPV control efforts will increasingly require.

Subject of Research: Prevalence and genotype distribution of human papillomavirus infection among male outpatients in Putian, Fujian Province, China

Article Title: Prevalence and genotype distribution characteristics of human papillomavirus infection among male outpatients in Putian, Fujian Province: a retrospective study

Article References: Chen, Y., Xiao, G., Chen, A., Zhang, R., & Zhang, L. (2026). Prevalence and genotype distribution characteristics of human papillomavirus infection among male outpatients in Putian, Fujian Province: a retrospective study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14565-z

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14565-z

Keywords: HPV, human papillomavirus, male HPV prevalence, genotype distribution, HPV vaccination, 9-valent vaccine, high-risk HPV, genital warts, dermatitis, China, epidemiology, BMC Infectious Diseases

The study, led by Mihir M. Shah of Stanford University School of Medicine together with Arash Pour Mohammad, Mahi Bhatt, Justin M. Ko, and Gordon H. Bae of the Stanford Department of Dermatology, examined patterns of nonsteroidal topical prescribing for dermatitis across different insurance categories. Drawing on Epic Cosmos, one of the largest aggregated electronic health record databases in the United States, the researchers were able to compare how patients with public insurance, private commercial coverage, and other payer types fared when it came to access to these medications. The central finding is stark in its simplicity: insurance type is associated with reduced use of nonsteroidal topical therapies for dermatitis, meaning that patients covered by certain plans, particularly public programs, were less likely to have these treatments documented in their records than patients with other forms of coverage.

The technical rationale for why this matters begins with the biology of atopic dermatitis itself. The disease is driven by a dysregulated type 2 immune response, with elevated signaling through interleukin-4 and interleukin-13, impaired epidermal barrier function, and chronic activation of T cells in the skin. Topical corticosteroids remain the workhorse of therapy because they are broadly anti-inflammatory and inexpensive, but their long-term use is limited by well-characterized adverse effects. Calcineurin inhibitors work downstream of T cell receptor signaling, blocking the calcineurin–nuclear factor of activated T cells pathway and thereby reducing transcription of inflammatory cytokines. Crisaborole inhibits phosphodiesterase-4, elevating intracellular cyclic AMP and damping inflammatory mediator release. Topical JAK inhibitors interrupt cytokine signaling at the receptor level. Each of these mechanisms offers steroid-free control of flares, and clinical guidelines increasingly position them as first-line or maintenance options, especially for sensitive anatomical sites.

Access to these molecules, however, is mediated not by guidelines but by formularies. A companion analysis published in the same journal by Kim and colleagues in 2024 found that Medicaid coverage for nonsteroidal topical atopic dermatitis treatment is often restrictive and highly variable across the United States, with state-by-state differences in prior authorization requirements, step therapy mandates, and quantity limits. Step therapy, the practice of requiring patients to fail on cheaper agents before escalating, is particularly consequential in dermatology, because a patient may need to document inadequate response or adverse reaction to multiple topical corticosteroids before a nonsteroidal agent is approved. Prior authorization adds administrative delay, and in a relapsing condition like atopic dermatitis, delays during a flare translate directly into suffering, sleep loss, and, in children, potential developmental and psychosocial consequences.

The Stanford team’s findings fit into a broader and troubling literature on dermatologic health equity. A 2023 retrospective matched cohort study by Al-Obaydi, Craig, and Al-Shaikhly documented racial and ethnic disparities in the treatment of atopic dermatitis patients in the United States, showing that Black and Hispanic patients receive guideline-concordant therapy at lower rates than white patients. Because race, socioeconomic status, and insurance type are deeply intertwined in the American system, with Black and Hispanic populations disproportionately enrolled in Medicaid, insurance-based barriers to nonsteroidal topicals may function as a structural mechanism that perpetuates and amplifies racial disparities in eczema outcomes. A 2025 Kaiser Family Foundation analysis of health coverage by race and ethnicity from 2010 through 2023 underscores how unevenly coverage types are distributed across the population, making payer status a plausible and measurable proxy for structural disadvantage.

What makes the new report particularly valuable is its methodology. Epic Cosmos aggregates de-identified longitudinal records from hundreds of health care organizations participating in the Epic electronic health record network, giving researchers a window into real-world prescribing behavior across geographically and demographically diverse populations. Rather than relying on claims data, which capture prescriptions filled but not the clinical context in which they were considered, the electronic health record approach allows investigators to identify patients with dermatitis diagnoses and examine what therapies were actually documented in their care. The retrospective design is exempt from informed consent requirements and did not constitute human subjects research requiring institutional review board approval, and the authors declare no conflicts of interest and report no external funding, an increasingly rare transparency profile in dermatologic research that is often supported by pharmaceutical industry grants.

The study does have limitations inherent to its design and data source, and these deserve honest acknowledgment. Because the data are observational, the association between insurance type and nonsteroidal topical use cannot be interpreted as proof that coverage policies directly cause the prescribing gap; unmeasured confounders such as disease severity, patient preference, geographic access to dermatologists, and clinician practice patterns may contribute. The proprietary nature of the Epic Cosmos database, governed by data use agreements, means the underlying data cannot be shared publicly and access is restricted to authorized researchers affiliated with participating health care organizations, which limits independent replication. Nevertheless, the consistency of the finding with prior formulary analyses strengthens the biological and policy plausibility of the association: if Medicaid plans systematically restrict nonsteroidal topicals, lower documented use among Medicaid beneficiaries is exactly what one would expect to observe.

The clinical stakes of this prescribing gap are not trivial. Untreated or undertreated atopic dermatitis carries a heavy burden: chronic sleep disruption from nocturnal pruritus, increased risk of skin and systemic infections including eczema herpeticum, higher rates of anxiety and depression, and, in severe cases, associations with cardiometabolic and atopic comorbidities. The so-called itch–scratch cycle perpetuates barrier damage and inflammation, and early aggressive control of disease in childhood may influence the atopic march, the progression from eczema to food allergy, allergic rhinitis, and asthma. Denying or delaying access to effective steroid-sparing agents forces clinicians into a corner: either overuse topical corticosteroids in situations where nonsteroidal agents would be preferable, or under-treat the disease. Both paths carry costs, and both fall disproportionately on patients whose insurance makes the modern alternatives hardest to obtain.

The policy implications are equally clear. A 2024 evaluation by Loiselle and colleagues of prescription medication access in the atopic dermatitis population in the United States documented systemic barriers to reaching therapy, and the new findings add a specific, actionable target: harmonizing and relaxing Medicaid coverage criteria for nonsteroidal topical therapies. Because Medicaid is jointly administered by states and the federal government, reform could occur at multiple levels, from state Medicaid formulary committees revising prior authorization criteria to federal guidance encouraging uniform coverage of guideline-supported dermatologic therapies. Clinicians, meanwhile, can respond in the near term by documenting medical necessity meticulously, appealing denials, and using patient assistance programs where available. What the Stanford report ultimately exposes is a quiet form of rationing, one that operates not at the pharmacy counter but in the invisible machinery of formulary design, and one that patients with eczema pay for in sleepless nights and inflamed skin.

Subject of Research: Insurance-related disparities in access to nonsteroidal topical therapies for dermatitis

Article Title: Insurance type is associated with reduced use of dermatitis nonsteroidal topical therapies

Article References: Shah, M. M., Pour Mohammad, A., Bhatt, M., Ko, J. M., & Bae, G. H. (2026). Insurance type is associated with reduced use of dermatitis nonsteroidal topical therapies. Archives of Dermatological Research, 318(1), Article 478. https://doi.org/10.1007/s00403-026-04956-2

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04956-2

Keywords: atopic dermatitis, dermatitis, nonsteroidal topical therapies, insurance, Medicaid, health disparities, calcineurin inhibitors, crisaborole, topical JAK inhibitors, electronic health records, health policy, dermatology